(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID
生物活性靶点体外研究体内研究 用途与合成方法 MSDS (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID价格(试剂级) 上下游产品信息
| 中文名称 | (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID |
|---|---|
| 中文同义词 | (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-7,8,17-三羟基-4,9,11,13,15,19-二十二碳六烯酸;消退素D1;化合物 T13864 |
| 英文名称 | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid |
| 英文同义词 | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid;Resolvin D1;RVD1;(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID;resolvin D1, CID73755062;OIWTWACQMDFHJG-CCFUIAGSSA-N;Resolvin D1 Exclusive;4,9,11,13,15,19-Docosahexaenoic acid, 7,8,17-trihydroxy-, (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)- |
| CAS号 | 872993-05-0 |
| 分子式 | C22H32O5 |
| 分子量 | 376.49 |
| EINECS号 | |
| 相关类别 | 试剂盒-细胞分析试剂盒 |
| Mol文件 | 872993-05-0.mol |
| 结构式 |  |
(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID 性质
| 储存条件 | Store at -80°C,protect from light |
|---|---|
| 溶解度 | DMF：50 mg/ml；乙醇：50 mg/ml； PBS（pH 7.2）：0.05 mg/ml |
| 形态 | 液体 |
| 颜色 | 无色至浅黄 |
Resolvin D1 (RvD1) 是炎症的一种内源性促分解介质，衍生自在急性炎症的缓解阶段的 omega-3二十二碳六烯酸。Resolvin D1 通过调节肌动蛋白聚合来阻止促炎性中性粒细胞迁移，减少巨噬细胞中 TNF-α 介导的炎症，并增强巨噬细胞对凋亡细胞的吞噬作用。
|
Human Endogenous Metabolite
|
Resolvin D1 (RvD1) (1-100 nM; 15 minutes) induces dose-dependent short-term functional changes in primary human macrophages. RvD1 triggers intracellular Ca 2+ release, blocks chemotactic migration, and stimulates phagocytosis of microbial particles with maximal efficiency at 10 nM. Resolvin D1 (0-500 nM; 72 hours) shows a strong inhibition of LPS-induced TRAP and cathepsin K expression by RvD1 at different concentrations in RAW264.7 macrophages.
Resolvin D1 (RvD1) (100-1000 ng; i.p.; daily on days 10) improves RA (rheumatoid arthritis) clinical endpoints in arthritic mice.
| Animal Model: | 18-20 g thirty 8-week-old female DBA/1J mice (collagen antibody-induced arthritis (CAIA)) |
| Dosage: | 100, 500, and 1000 ng (or 1000 ng, daily on days 4-10) |
| Administration: | i.p. injection; daily on days 10 |
| Result: | Exhibit a reduced arthritic score. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-125527 | (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID Resolvin D1 | 872993-05-0 | 25μg(265.6μM * 250μL in Ethanol) | 8500元 |